Cullinan Oncology Inc — Balance Sheet (NASDAQ:CGEM) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics

Quarterly Annual

Total assets 437.19 M561.12 M484.18 M621.82 M448.37 M Total liabilities 11.81 M26.09 M30.29 M31.5 M39.64 M Total equity 425.37 M535.03 M453.89 M590.33 M408.73 M Total liabilities & shareholders' equities 437.19 M561.12 M484.18 M621.82 M448.37 M Total debt ——5.59 M2.15 M— Net debt ——-461.48 M-396.85 M—

Haberler

Clear Street, Gilead anlaşmasıyla Cullinan Oncology hissesi için tavsiyesini yineledi

Stifel, Cullinan Oncology’nin hisse hedefini yükseltti

Stifel raises Cullinan Oncology stock price target on autoimmune progress

Cullinan Therapeutics: Thesis Strengthening For T-Cell Engager Specialist (NASDAQ:CGEM)

Cullinan Therapeutics, Inc. (CGEM) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

TheStreet Pro Analysts Say, “Big Tech Names are Anything But Cheap – Buy These 2 Stocks Instead” - TipRanks.com

Guggenheim, Cullinan Oncology hissesini Al tavsiyesi ve 30 dolar hedef fiyatla takibe aldı

Guggenheim initiates Cullinan Oncology stock with Buy rating, $30 target

Cullinan Therapeutics Stock: Cash-Rich Biotech With Multiple Value Drivers (NASDAQ:CGEM)

Are Medical Stocks Lagging AIM ImmunoTech (AIM) This Year?

Here's What Could Help Cullinan Therapeutics (CGEM) Maintain Its Recent Price Strength

Cullinan Therapeutics, önemli otoimmün programları için veri açıklamaları planlıyor